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Our recent genome-wide allelotyping analysis of gallbladder carcinoma identiﬁed 3p, 8p, 9q and 22q as chromosomal regions
with frequent loss of heterozygosity. The present study was undertaken to more precisely identify the presence and location
of regions of frequent allele loss involving those chromosomes in gallbladder carcinoma. Microdissected tissue from 24
gallbladder carcinoma were analysed for PCR-based loss of heterozygosity using 81 microsatellite markers spanning
chromosome 3p (n=26), 8p (n=14), 9q (n=29) and 22q (n=12) regions. We also studied the role of those allele losses in
gallbladder carcinoma pathogenesis by examining 45 microdissected normal and dysplastic gallbladder epithelia accompanying
gallbladder carcinoma, using 17 microsatellite markers. Overall frequencies of loss of heterozygosity at 3p (100%), 8p (100%),
9q (88%), and 22q (92%) sites were very high in gallbladder carcinoma, and we identiﬁed 13 distinct regions undergoing
frequent loss of heterozygosity in tumours. Allele losses were frequently detected in normal and dysplastic gallbladder
epithelia. There was a progressive increase of the overall loss of heterozygosity frequency with increasing severity of
histopathological changes. Allele losses were not random and followed a sequence. This study reﬁnes several distinct
chromosome 3p, 8p, 9q and 22q regions undergoing frequent allele loss in gallbladder carcinoma that will aid in the positional
identiﬁcation of tumour suppressor genes involved in gallbladder carcinoma pathogenesis.
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Gallbladder carcinoma (GBC) is a relatively uncommon neoplasm
which demonstrates considerable geographic and gender variation
in incidence (Albores-Saavedra and Henson, 2000). For unknown
reasons, it is one of the most frequent neoplasms in Chile, where it
is the leading cause of cancer deaths in females (Lazcano-Ponce et
al, 2001). It has been well established that invasive GBC is preceded
by preneoplastic lesions, including dysplastic changes of the gallblad-
der epithelium (Albores-Saavedra and Henson, 2000). There is a very
limited information about the molecular changes involved in the
pathogenesis of GBC (Wistuba and Albores-Saavedra, 1999).
It is now well recognised that tumourigenesis is a multistep process
resulting from the accumulation of sequential genetic alterations
(Fearon and Vogelstein, 1990). In addition to oncogene activation,
inactivation of tumour suppressor genes (TSGs) has been shown to
play an important role in tumourigenesis (Fearon and Vogelstein,
1990). Allelic loss, manifested as loss of heterozygosity (LOH) at
polymorphic loci, is recognised as a hallmark of tumour suppressor
genes, whose other allele is inactivated by point mutations or by some
other mechanism (Knudson, 1985). Thus, the ﬁnding of chromoso-
mal regions with frequent incidence of LOH in a neoplasm
suggests that those regions may harbour one or more TSGs.
Our recent genome-wide allelotyping analysis on GBC indicated
that allelic losses at multiple sites of the genome are frequent in
this neoplasm (Wistuba et al, 2001). We identiﬁed at least 21 chro-
mosomal regions with frequent LOH in GBC, including 3p, 8p, 9q
and 22q regions. Allelic losses at those chromosome sites have been
implicated in the pathogenesis of several human neoplasms,
suggesting that there probably are several different TSGs located
in those chromosomal regions (Albrecht et al, 1994; Chaganti et
al, 1995; Habuchi et al, 1995; El-Naggar et al, 1998; Miyakawa et
al, 1998; Cheng et al, 1999; Wistuba et al, 1999a, 2000; Baffa et
al, 2000; Choi et al, 2000; Lerman and Minna, 2000; Muscheck
et al, 2000; Maitra et al, 2001).
The present study was undertaken to reﬁne the regions of
frequent allele loss involving chromosomes 3p, 8p, 9q and 22q in
GBC identiﬁed with in our recent genome-wide allelotyping analy-
sis (Wistuba et al, 2001). Using DNA extracted from archival
parafﬁn-embedded tissue of GBC, and a panel of high-resolution
polymorphic markers, we studied the shortest regions of overlap-
ping LOH on chromosomes 3p, 8p, 9q and 22q. We also studied
the role of those allele losses in GBC pathogenesis by examining
LOH on those four chromosomal arms in gallbladder epithelia
accompanying invasive GBC.
MATERIALS AND METHODS
Archival tumour specimens
Formalin-ﬁxed parafﬁn-embedded material from 24 surgically
resected primary invasive gallbladder carcinomas was obtained from
cholecystectomy specimens resected between 1990 and 1998 at the
Catholic University Medical School Hospital, Santiago, Chile, as
part of an Institutional Review Board approved study. The patients
consisted of 19 women and ﬁve men ranging in age from 51–85
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www.bjcancer.comyears (mean age, 68 years). Six (25%) were well differentiated, eleven
(46%) were moderately differentiated, and seven (29%) were poorly
differentiated tubulo-papillary adenocarcinomas. The majority of
the tumours were advanced GBCs (20 of 24 cases; 84%) with inva-
sion of the gallbladder serosa; the remaining (four of 24 cases; 16%)
were early GBCs, with invasion of the submucosa (one case; 4%) or
muscularis propia (three cases; 12%) of the gallbladder.
Normal epithelium and preneoplastic lesions
accompanying gallbladder cancer
Forty-ﬁve histologically discrete foci of non-invasive gallbladder
epithelia were identiﬁed adjacent to 20 GBCs, each consisting of
at least 1000 cells. These included 17 histologically normal epithelia
and 28 high-grade dysplasias (Figure 1). The dysplastic lesions were
scored using published criteria for their histopathological identiﬁ-
cation in the gallbladder epithelium (Albores-Saavedra and
Henson, 2000).
Microdissection and DNA extraction
Serial 5 mm sections were cut from archival, formalin-ﬁxed, paraf-
ﬁn-embedded tissues. Precise microdissection from archival
parafﬁn-embedded tissues was performed under microscopic visua-
lization using a micromanipulator, as described previously (Figure
1). From multiple serial sections of each case 4000 to 5000
sectioned tumour cells and 1000 gallbladder epithelial cells were
microdissected, and DNA extracted as described. Dissected
lymphocytes or normal stromal cells from the same slide were used
as a source of constitutional DNA. DNA from at least 200 cells
were used for each multiplex PCR reaction, as previously described
(Wistuba et al, 1998). In order to circumvent the possibility of arti-
factual LOH occurring in DNA extracted from the relatively small
non-tumour foci, fewer microsatellite markers were analysed to
ensure comparable numbers of cells being used for the initial
ampliﬁcation reaction in all samples.
Microsatellite DNA markers and PCR- LOH analysis
To evaluate LOH on GBC, we used primers ﬂanking 81 microsatellite
repeat polymorphisms spanning several 3p (n=26), 8p (n=14), 9q
(n=29) and 22q (n=12) regions showing high frequencies of LOH
in the genome-wide allelotyping analysis on GBC (Wistuba et al,
2001). The microsatellite markers tested are shown in Figures 2–5.
The markers were selected from the Genome Database (http://
www.gdb.org/). Subsets of markers (n=17) spanning a total of 12
chromosomal regions frequently deleted in invasive GBC (Table 1)
were used for the analysis of gallbladder epithelium (3p=6; 8p=4;
9q=4; and 22q=3). Because we used DNA extracted from archival
parafﬁn-embedded tissues, the amplicon size was restricted to less
than 250 bp. A two-round PCR strategy (multiplex PCR followed
by uniplex PCR) was utilised to amplify each marker, as described
previously (Wistuba et al, 1998). We optimised the PCR conditions
to perform 11 multiplex PCRs containing all 81 markers utilised in
this study. Each multiplex PCR contained six to eight microsatellite
markers. The list of multiplex sets and speciﬁc optimization condi-
tions we used are available upon request. A 108C ‘touch-down’
PCR strategy was used spanning the primers annealing temperature
followed by 25 cycles at the optimal annealing temperature. The ﬁnal
product was separated on a 6% denaturing polyacrylamide gel and
subjected to autoradiography. LOH was scored by visual detection
of complete absence of one allele of informative cases (Figures 2–5).
Data analysis
The data were analysed using a series of Microsoft Visual Basic
programmes speciﬁcally written for various computations or repe-
titive tasks in Microsoft Excel, including LOH frequencies,
breakpoint frequencies, colour-coded formatting of LOH patterns,
and clustering analysis, as described previously (Girard et al, 2000).
In order to determine the sequence of genetic abnormalities in the
multistep progression of GBC we utilised multiple microsatellite
markers (n=17) to examine LOH at 12 chromosomal regions
located on the four chromosomal arms examined. To determine
whether the losses were progressive in the sequential development
of GBC, we determined the frequency of loss of individual micro-
satellite markers (n=17) and chromosomal regions (n=12) using
the Fractional Allele Loss (FAL) index and the Fractional Regional
Loss (FRL) index, respectively. The FAL index is deﬁned as the
total number of microsatellite markers with LOH in an epithelial
sample divided by the total informative markers in the correspond-
ing normal DNA. The FRL index is deﬁned as the total number of
chromosomal regions with LOH divided by the total number of
informative regions in the corresponding normal DNA.
Statistical analysis was performed using the nonparametric
Wilcoxon and Fisher Exact tests. The cumulative binomial test
was used to examine the likelihood that the occurrence of a parti-
cular event (loss of the same allele in the invasive carcinoma and
an associated epithelial sample) occurs at a particular probability
when observed in repeated trials. When the results are compared
with a chance occurrence or nonoccurrence, the particular prob-
ability of comparison is 0.5. Probability values of P50.05 were
regarded as statistically signiﬁcant.
RESULTS
Deﬁnition of regions of loss in GBC
Overall frequencies of allelic loss at any 3p (24 out of 24 cases,
100%), 8p (24 out of 24 cases, 100%), 9q (21 out of 24 cases,
88%), and 22q (22 out of 24 cases, 92%) sites were very high in
GBCs. Most of the sites of allelic loss at all chromosomal arms
examined were localised, and the extent of the partial allele losses
was used to identify 13 discrete minimal regions of non-overlap-
ping allele losses (four for 3p; three for 8p; four for 9q; and two
for 22q). The patterns of LOH and frequencies of allelic loss at
different critical regions identiﬁed are shown in Figures 2–5 and
summarised in Table 2. Representative autoradiographs for cases
with partial loss of all four chromosomal arms demonstrating loss
and retention of neighbouring alleles in GBCs are illustrated in
Figures 2–5. Because artifacts resulting from PCR ampliﬁcation
may be mistaken for LOH, especially when minute amounts of
input DNA are utilised, approximately 30% of examples of LOH,
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Figure 1 Representative example of the precise microdissection techni-
que of invasive GBC (A and B) and high-grade dysplastic lesion (C and D)
used in this study. Note that only tumour and epithelial cells were micro-
dissected (A, C, before; B, D, after) while stromal tissue is intact.
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conﬁrmation from newly microdissected material and identical
LOH pattern were detected.
Patterns of loss in GBC
Although most of the losses at all chromosomal arms examined
were localised, the data demonstrate that in chromosomes 3p, 8p
and 9q the most frequently observed pattern was loss of two or
more regions. Thus, allelic loss of a single region in each of those
chromosomes by itself was a relatively infrequent event. Two or
more regions were lost in 84% at 3p, 73% at 8p, 63% at 9q,
and 52% at 22q. Cluster analysis to examine if allelic loss at one
chromosomal region was linked to changes at another region
(Girard et al, 2000) did not reveal any concordance between
markers from the same or different chromosomes.
Allelic loss in normal and dysplastic gallbladder epithelia
accompanying tumours
Allelic loss at one or more 3p, 8p, 9q and 22q regions was detected
in the majority of the histologically normal (15 out of 17, 88%) and
dysplastic (26 out of 28, 93%) foci examined (Table 1). The FAL
(Fractional Allelic Loss) and FRL (Fractional Regional Loss) indices
were calculated as an expression of the amount of allele loss, and an
increasing severity of histological changes was characterised by a
signiﬁcant rise of both index means (P50.001; Table 1).
The pattern of allelic loss was not random, and losses at one or
more 3p (54%) and 8p (50%) regions were the most frequently
detected abnormalities in histologically normal epithelium (Table
1). While 9q allelic loss was relatively frequent (29%) in normal
epithelium, losses at 22q commenced at the dysplasia stage. For
most of the chromosomes examined (3p, 8p and 22q), the differ-
ences between dysplasia and invasive carcinoma were modest and
not signiﬁcant. Data on individual epithelial and tumour samples
are pooled in Figure 6. As minute amounts of input DNA were
utilised, all examples of LOH from the histologically normal
epithelia and nearly half from the dysplasia were repeated for
conﬁrmation.
Patterns of allelic loss in the pathogenesis of GBC
To determine the sequential molecular changes involved in the
development of GBC, we analysed the pattern of allele losses
detected in the GBC tumours and their accompanying normal
and dysplastic epithelia. We considered only 14 tumours and 30
accompanying normal (n=11) and dysplastic (n=19) epithelial
specimens that were informative for at least one marker in each
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3p25
3p22–24
3p21
3p14654
3p12
D3S1597
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D3S1351
D3S2432
D3S1612
D3S1029
D3S1478
D3S1447
D3S4597
D3S4604
D3S4614
D3S4622
D3S4623
D3S4624
D3S1573
D3S1582
D3S1076
ITIH-1
D3S1766
D3S1234
D3S4103
D3S1300
D3S1284
D3S1274
D3S1577
D3S1511
Tumours
1     5    4     23 24     7  13   16  12   19    6    8    9   14    3   10  18   21    2  17    20  15  11   22
LOH
Frequency
Markers
(%)
Regions
R1 8/18(44%)
R2 14/21 (67%)
R3 16/24 (67%)
R4 12/15 (80%)
27
38
19
50
29
36
39
33
50
50
42
73
32
27
47
64
8
31
21
60
28
35
60
73
24
64
Case 8
D3S1029 D3S4622 D3S1766 D3S1234 D3S1300 D3S1274 D3S1577
L    T L    T L    T L    T L    T L    T L    T L    T
—
—
—
—
—
—
—
—
—
—
—
—
—
—
No LOH
LOH
Not informative
Figure 2 Patterns of chromosome 3p allele losses in gallbladder carcinoma. The cases have been arranged from left to right in decreasing order of chro-
mosome 3p allele losses. Markers are placed in the predicted order from 3pter-cen. Four regions (R1–R4) having frequent allelic losses are shown. Lower
panel: seven autoradiographs showing discrete allele loss at chromosome 3p in a microdissected GBC case (case 8) demonstrating loss and retention of
neighbouring alleles. L, lymphocytes or normal stromal cells; T, microdissected invasive GBC. Horizontal bars on the left of the autoradiographs indicate the
main allelic bands.
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dysplastic focus showed no LOH at any chromosomal arm and
was excluded from this analysis. Three patterns of allelic loss were
discerned in the 30 histologically normal, dysplastic and neoplastic
foci: (a) Early pattern, with only 8p loss or 8p accompanied with
3p. (b) Intermediate pattern, with only 9q loss or 9q accompanied
with 3p and/or 8p. (c) Advanced pattern, with 22q loss accompa-
nied with 8p+3p or 8p+9q or 8p+3p+9q. Of interest, normal
gallbladder epithelium had only early (55%) and intermediate
(45%) patterns, while tumours had advanced (71%) and inter-
mediate (29%) patterns. Dysplastic gallbladder epithelia
demonstrated the entire spectrum of patterns, including the
advanced (56%), intermediate (30%) and early (14%).
Allele speciﬁc mutations vs potential clonal relationship of
epithelial foci
Previous studies in gallbladder carcinoma and other neoplasms
demonstrated that at any one locus, loss of parental alleles was
not random, and that there was a strong tendency for the identical
allele to be lost in all non-neoplastic and neoplastic foci examined
(Wistuba et al, 1995, 1999b). We refer to this phenomenon as allele
speciﬁc mutation (ASM) (Wistuba et al, 1995, 1999b). We deter-
mined the frequencies of ASM in the 61 epithelial and tumoural
foci demonstrating one or more sites of allelic loss in 20 GBC
cases. For all 146 comparisons involving 17 microsatellite markers,
the same parental allele was lost in 128 (88%). The possibility that
this occurred by chance alone is extremely remote as tested by the
cumulative binomial test (P=5.3610
722).
Because in the GBC there is a close morphological relationship
between invasive carcinoma and its dysplastic lesions (Albores-
Saavedra and Henson, 2000) we then examined the possibility that
cancer and non-malignant gallbladder epithelia were clonally
related, using the speciﬁc alleles lost to mark the different foci in
individual cases. Possible evidence of a clonal relationship (through
sequential changes) were present only in 10 (16%) out of 61 foci
examined. In most (84%) of the normal and dysplastic epithelia
the patterns of allele loss suggested that they arose as independent
clones. However, we cannot exclude the possibility that the lesions
represent subclones from a precursor clone having some initial
molecular change, which we did not examine. Despite this lack
of clonal relationship ASM was still signiﬁcantly detected even in
the analysis of clonally unrelated foci (104 of 123 comparisons,
85%; P=9.1610
726).
Microsatellite instability (MSI) in GBC pathogenesis
We detected a relatively high frequency of MSI at one or more 3p,
8p, 9q and 22q chromosomal loci in one of 13 (8%) of histologi-
cally normal foci, in four of 54 (7%) dysplastic foci and in six of 12
(50%) invasive carcinomas examined (data not shown).
DISCUSSION
Our recent genome-wide allelotyping analysis indicated that allelic
losses at multiple sites of the genome are frequent in GBC, and indi-
cated for the ﬁrst time that in addition to 3p and 8p, LOH on 9q
and 22q may also play a role in the pathogenesis of this neoplasm
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1      9    20    4   12   18   24    6   7    10   11   15   16  21  17     2    8   13  19    23   3    5    14   22
LOH
Frequency
Markers
(%)
Regions
R1 13/23 (55%)
R2 142/24 (59%)
R3 15/23 (65%)
Case 20
D8S1130 D8S549 D8S258 D8S133 D8S137
L    T L    T L    T L    T L    T L    T L    T
8p
8p23
8p22
8p21
LPL NEFL
—
—
—
—
—
—
—
—
—
—
—
—
—
—
D8S277
D8S1130
D8S1106
D8S549
D8S254
D8S261
LPL
D8S258
D8S133
D8S136
NEFL
D8S1113
D8S1477
D8S137
56
40
47
44
46
50
55
50
53
53
50
25
58
20
No LOH
LOH
Not informative
Figure 3 Patterns of chromosome 8p allele losses in gallbladder carcinoma. The cases have been arranged from left to right in decreasing order of chro-
mosome 8p allelic losses. Markers are placed in the predicted order from 8pter-cen. Three regions (R1–R3) having frequent allelic losses are shown. Lower
panel: seven autoradiographs showing discrete allele loss at chromosome 8p in a microdissected GBC case (case 20) demonstrating loss and retention of
neighbouring alleles. L, lymphocytes or normal stromal cells; T, microdissected invasive GBC. Horizontal bars on the left of the autoradiographs indicate the
main allelic bands.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 432–440(Wistuba et al, 2001). We identiﬁed at least 21 chromosomal regions
with frequent LOH in GBC, including sites on 3p, 8p, 9q and 22q,
suggesting that those chromosome regions may harbour putative
TSGs that are inactivated in the development of this tumour. This
previous study was a low-density screen in order to elucidate chro-
mosomal hot spots for subsequent detailed analysis.
The present study with high-density allelotyping have conﬁrmed
and extended the previous ﬁndings. The overall frequencies of allelic
lossatany3p(100%),8p(100%),9q(88%), and22q(92%)siteswere
very high in our tumours. Overall, thirteen distinct sites of frequent
allele loss in GBC at chromosome 3p, 8p, 9q and 22q (summarised
inTable2)weredetectedinthepresentstudy,andthemajorityofthese
have not previously been described in this neoplasm. The location of
these sites was based on the determination of the minimal region of
loss that is deﬁned by the occurrence of ‘breakpoints’ surrounding
regions of frequent LOH. These sites are likely to represent TSG
regions that are lost in GBC and warrant further investigation.
As a result of our detailed allelotyping 3p analysis on GBC, we
were able to identify multiple areas of discontinuous LOH and four
distinct 3p regions (3p22-24; 3p21.3; 3p14.2; and 3p12) with
frequent allelic loss in this tumour. Several candidate TSGs have
been detected in those 3p regions with frequent allele losses in
GBC. One candidate in the 3p22-24 region is the retinoic acid
receptor-beta (RARb) gene (Virmani et al, 2000). Another candi-
date gene, the fragile histidine triad (FHIT) gene, spans the
FRA3B fragile site at 3p14.2 (Huebner et al, 1998). A new candi-
date TSG, ROB01 (DUTT1), has been cloned residing in the
U2020 3p12 deletion region at marker D3S1274 (Sundaresan et
al, 1998). Currently two distinct 3p21.3 regions are under study
because of the existence of multiple homozygous allele loss in lung
and breast cancer cell lines (Lerman and Minna, 2000). One of
those was tested in this report by markers D3S4614 and
D3S4622, and represents a minimal region of frequent allele losses
(67%) in our GBC cases. Recently, a new candidate TSG located in
this region, the human RAS effector homologue (termed RASSF1A)
gene, has been shown to have tumour suppressing function and
undergoes epigenetic inactivation in several cancers (Dammann et
al, 2000; Burbee et al, 2001; Dreijerink et al, 2001).
Our detailed allelotyping analysis of the 8p21-23 region demon-
strated three distinct regions with frequent allelic loss on GBC,
namely 8p23, 8p22, and 8p21. The 8p21 region, deﬁned by the same
markerstestedinourGBCs,hasbeendescribedwithfrequentalleleloss
in other tumour types (Trapman et al, 1994; Farrington et al, 1996;
Baffaetal,2000).Theplatelet-derivedgrowthfactorreceptor-likegene
(PRLTS) candidate TSG is centromeric to our 8p21 minimal region
(Fujiwara et al, 1995). The 8p22 region identiﬁed in our GBCs spans
the FEZ1/LZTS1 gene, a candidate TSG, whose expression is altered
in multiple human tumours (Ishii et al, 1999; Cabeza-Arvelaiz et al,
2001).TheN33geneat8p22wasfoundtobesilencedinseveralcancer
cells, although no point mutations have been identiﬁed (Bookstein et
al, 1997). Allele losses at the telomeric 8p23 region, shown to be
frequent in our gallbladder tumours, has been previously described
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D9S155
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D9S60
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Figure 4 Patterns of chromosome 9q allele losses in gallbladder carcinoma. The cases have been arranged from left to right in decreasing order of chro-
mosome 9q allele losses. Markers are placed in the predicted order from 9qcen-ter. Four regions (R1–R4) having frequent allelic losses are shown. Lower
panel: eight autoradiographs showing discrete allele loss at chromosome 9q in a microdissected GBC case (case 17) demonstrating loss and retention of
neighbouring alleles. L, lymphocytes or normal stromal cells; T, microdissected invasive GBC. Horizontal bars on the left of the autoradiographs indicate the
main allelic bands.
Gallbladder carcinoma and chromosomes 3p, 8p, 9q and 22q
II Wistuba et al
436
British Journal of Cancer (2002) 87(4), 432–440 ã 2002 Cancer Research UKG
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Tumours
10   15   20    21  23   1    2     3     4     5    6    7     9   11  16   19  14  18      8   12   22   24  13  17
LOH
Markers
(%)
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R2 14/24 (58%)
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D22S345
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D22S445
D22S283
D22S284
Frequency
46
33
14
27
17
4
55
56
33
32
33
33
No LOH
LOH
Not informative
Figure 5 Patterns of chromosome 22q allele losses in gallbladder carcinoma. The cases have been arranged from left to right in decreasing order of
chromosome 22q allele losses. Markers are placed in the predicted order from 22qcen-ter. Two regions (R1–R2) having frequent allelic losses are shown.
Lower panel: six autoradiographs showing discrete allele loss at chromosome 22q in a microdissected GBC case (case 20) demonstrating loss and retention
of neighbouring alleles. L, lymphocytes or normal stromal cells; T, microdissected invasive GBC. Horizontal bars on the left of the autoradiographs indicate the
main allelic bands.
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Figure 6 Summary of all allelotyping results by chromosome arms in the pathogenesis of GBC. A total of 69 specimens are shown, including all 24 invasive
carcinomas and all 45 non-malignant epithelium (17 histologically normal appearing and 28 dysplastic epithelia) accompanying GBCs. The specimens have
been sorted from left to right in ascending number chromosome arm allele losses. The sources of the various specimens are coded above the boxes and
include normal epithelium (N), dysplasia (D) and tumour (T). Lower panel: eight autoradiographs showing discrete allele loss at chromosomes 3p, 8p, 9q y
22q in two GBCs and their accompanying non-malignant epithelium. L, lymphocytes or normal stromal cells; N, normal epithelium; D, dysplasia; T, micro-
dissected invasive GBC. Horizontal bars on the left of the autoradiographs indicate the main allelic bands. Data analysis shows that allelic losses present in
normal and dysplastic epithelia were not random. Analysis of informative samples for all four chromosome arms shows that most normal epithelia demon-
strate 8p or 8p+3p losses and the majority of dysplasias have losses on 8p and/or 3p with 9q and/or 22q, sugesting a sequential model of genetic abnorm-
alities that begins with 8p LOH and progresses through 3p, 9q and 22q losses.
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et al, 1999; Pineau et al, 1999; Ishwad et al, 1999). However, no candi-
date genes have been reported on this region.
At 9q, four different regions of frequent allele losses in GBC
were detected, namely 9q31, 9q31-33, and two sites at 9q34.2-
34.3. While the 9q31 minimal region has not been previously
described in other tumour types, allele losses at the 9q32-33 and
9q34 regions have been frequently reported in other neoplasms
(Chaganti et al, 1995). The 9q32-33 minimal region has been
intensively studied in transitional cell carcinoma of the urinary
bladder (Habuchi et al, 1998, 2001), being designated as DBC1
locus (for deleted in bladder cancer gene 1). A novel candidate
gene for this region has been identiﬁed and designated as DBCCR1
(Habuchi et al, 1998, 2001). At least two regions of minimal allele
losses involving the telomeric 9q34.2-34.3 region were detected in
GBC. These regions encompass one of the loci identiﬁed for the
tuberous sclerosis gene (TSC) (van Slegtenhorst et al, 1997).
We have detected two distinct sites of frequent allelic loss in GBC,
22q11.2 and 22qq12.2-q12.3 regions. Both regions have been
described with frequent allele losses in other neoplasms. The centro-
meric 22q11.2 region has been previously reported in hepatocellular
(Takahashi et al, 1993) and breast carcinomas (Allione et al, 1998);
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Table 1 Summary of allelic loss at 3p, 8p, 9q and 22q arms using 17 microsatellite marker loci on GBC and accompanying dysplastic and histologically
normal epithelial foci
Normal epithelium Dysplasia Invasive carcinoma
Region Markers N=17 N=28 N=20
Any 3p 7/13 54% 12/14 86% 13/15 87%
3p22–24 R1 D3S2432 4/7 57% 4/5 80% 6/10 60%
3p21.3 R2 D3S4622 1/7 14% 5/9 56% 6/8 75%
3p14.2 R3 D3S1234 0/9 0% 4/11 36% 7/13 54%
3p12 R4 D3S1274–D3S1284–D3S1511 6/9 67% 71/10 70% 7/10 70%
Any 8p 7/14 50% 15/26 58% 10/16 63%
8p23 R1 D8S277 1/7 14% 2/11 18% 7/9 78%
8p22 R2 D8S261 2/6 33% 6/17 35% 3/5 38%
8p21 R3 D8S136–NEFL 3/13 23% 10/24 42% 8/15 53%
Any 9q 4/14 29% 11/19 58% 13/16 81%
9q22–31 R2 D9S155 1/7 14% 5/12 42% 6/11 55%
9q34 R3 D9S1199 0/8 0% 1/11 9% 7/10 70%
9q34 R4 D9S66–D9S122 1/7 14% 7/15 47% 9/13 69%
Any 22q 0/8 0% 9/17 53% 9/13 69%
22q12 R2 D22S929–D22S281 0/7 0% 7/15 47% 5/9 56%
22q13 – D22S283 0/7 0% 3/17 18% 4/9 44%
Any chromosome – 15/17 88% 26/28 93% 20/20 100%
Indices
FAL
a – 0.23 0.39 0.55
FRL
a – 0.25 0.44 0.59
aFAL=Fractional Allele Loss;
bFRL=Fractional Regional Loss.
Table 2 Summary of allelic loss at 13 chromosomal regions on 3p, 8p, 9q and 22q examined in gallbladder carcinoma (n=24)
Chromosomal Region Reference Informative LOH Putative
region markers marker % N % tumor suppressor genes
3p arm
3p22–24 D3S1351–D3S2432 D3S2432 75 8/18 44 RARb
3p21.3 D3S4614–D3S4623 D3S24622 88 14/21 67 RASFFIA and 8 other genes
3p14.2 D3S1234–D3S1300 D3S1234 100 16/24 67 FHIT
3p12 D3S1284–D3S1274 D3S1274 63 12/15 80 ROB01 (DUTT1)
8p arm –
8p23 D8S277–D3S1130 D8277 96 13/23 57
8p22 D8S254–LPL D8S261 100 12/24 50 FEZ1, N33
8p21 D8S133–NEFL D8S136 96 15/23 65 PRLST
a
9q arm
9q31 D9S127–D9S58 D9S58 71 12/17 71 –
9q31–33 KM9.5–AFMA239 D9S155 83 11/20 55 BCCR1
9q34.2–34.3 D9S1198–D9S1199 D9S1198 75 11/18 61 TSC1
b
9q34.2–34.3 D9S66–D9S122 D9S122 79 11/19 58 TSC1
b
22q arm
22q11.2 D22S420–D22S264 D22S420 83 12/20 60 –
22q12.2–12.3 D22S929–D22S281 D22S281 100 14/24 58 NF2
aPRLST gene is centromeric to the region detected in gallbladder carcinoma.
bBoth regions encompass the TSC1 locus.
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British Journal of Cancer (2002) 87(4), 432–440 ã 2002 Cancer Research UKhowever, no candidate TSG has been reported at this site. The
22q12.2-q12.3 region encompasses the neuroﬁbromatosis type 2
(NF2) gene, a candidate TSG at this region (Rouleau et al, 1993).
Because NF2 gene mutations are rarely seen in epithelial tumours
with high frequency of allele losses at the NF2 gene locus (Takahashi
et al, 1993; Engleﬁeld et al, 1994; Allione et al, 1998; Miyakawa et al,
1998), an additional TSG involved in tumourigenesis could be
located at this region.
In several neoplasms it has been established that multiple sequen-
tial genetic changes are associated with the development of invasive
tumours. However, few investigators have focused in the genetic
abnormalities involved in the development of gallbladder carcinoma.
We and others (Wistuba et al, 1995; Chang et al, 1999) have reported
a high incidence of allelic loss at several chromosomal regions (17p-
TP53, 9p21-p16/CDKN2, and 5q22-APC/MCC region) occurring
early during the sequential pathogenesis of GBC. The present ﬁndings
of frequent chromosome 3p, 8p, 9q and 22q allele losses in non-
malignant gallbladder epithelia conﬁrm and greatly extend the ﬁnd-
ings that molecular changes commence early (in histologically
normal epithelium) during the sequential pathogenesis of GBC.
Our major ﬁndings regarding the molecular pathogenesis of GBC
are: (1) molecular changes preceded the onset of histologically recog-
nisable changes and 88% of the normal histologically normal foci
have allele loss at one or more chromosomal regions examined. (2)
There was a progressive increase of the overall LOH frequency
expressed by the FAL and FRL indices, with increasing severity of
histopathological changes. The development of epithelial cancers
requires multiple mutations (Fisher, 1958), and the stepwise accumu-
lation of these mutations may represent an inherent mutator
phenotype (Loeb, 1991). Thus, it is likely that those preneoplastic
lesions that have accumulated multiple mutations are also the ones
at higher risk for progression to invasive cancer. (3) Allelic losses
present in normal and dysplastic epithelia were not random. The
most frequent regions of allelic loss at normal epithelium occurred
at 3p and 8p. While 9q allelic losses were present mainly in dysplastic
lesions, losses at 22q were only detected in advanced lesions (dyspla-
sia and invasive carcinoma). By examining all our material for 3p, 8p,
9q and 22q allele loss, we propose a sequential model of genetic
abnormalities that begins with 8p LOH and progresses through 3p,
9q and 22q. 4) The same parental allele was frequently lost (88% of
comparisons) in non neoplastic lesions as in the corresponding inva-
sive carcinomas. We refer to this phenomenon as allele speciﬁc
mutation (ASM). We have documented this phenomenon in several
neoplasms (Wistuba et al, 2000; Maitra et al, 2001), including GBC
(Wistuba et al, 1995). The mechanism underlying ASM remains
unknown. Possibilities include the following: (a) seeding of multiples
sites in the gallbladder epithelium with a common progenitor clone;
(b) inhereted differences (e.g., polymorphism) in alleles that deter-
mine their susceptibility to loss; and, (c) potential epigenetic
differences in alleles that arise during development (e.g., methyla-
tion) that might predispose one to preferential loss. Since there is a
close morphological relationship between invasive carcinoma and
dysplastic lesions (Albores-Saavedra and Henson, 2000), we exam-
ined the possibility that the ASM phenomenon represented clonal
relationship due to a seeding or spread in the gallbladder epithelium
from a common progenitor clone. However, our ﬁndings that most
(84%) of the normal and dysplastic gallbladder epithelia accompany-
ing invasive tumours arose as independent clones suggest that ASM
has a different basis than clonality in GBC, such as inhereted suscept-
ibility to loss or potential epigenetic differences that might predispose
to preferential allele loss.
Alterations in microsatellite size, microsatellite instability (MSI),
are present in many cancers, including GBC (Wistuba et al, 1995),
and reﬂect a form of genetic instability. We found MSI in 50% of
the invasive GBC tumours and in lesser percentages of histologi-
cally normal and dysplastic foci. The mechanism involving MSI
in GBC need to be further studied.
In summary, allele losses of chromosome 3p, 8p, 9q and 22q
regions are frequent in GBC. Our data identiﬁes 13 distinct regions
of loss on those chromosomal arms, many of which harbour one
or more candidate TSGs, which may play a role in GBC pathogen-
esis. These regions have previously been reported to be frequently
lost in several human cancers, suggesting that may harbour TSGs
whose inactivation may be critical to the process of tumourigen-
esis. In addition, our ﬁndings in the non-malignant gallbladder
epithelium indicate that multiple, non-random and sequential
allele speciﬁc abnormalities commence early in the multistage
pathogenesis of GBC. These ﬁndings should be useful for the iden-
tiﬁcation of the TSGs involved in the pathogenesis of GBC, with
the potential for deﬁning molecular markers for early detection
as well as for the development of gene therapy strategies of this
highly malignant neoplasm.
ACKNOWLEDGEMENTS
Supported by grant FONDECYT (Fondo Nacional de Desarrollo
Cientiﬁco y Tecnologico) 1990489 (II Wistuba), the G Harold and
Leila Y Mathers Charitable Foundation, and CA71618 (JD Minna)
REFERENCES
Albores-Saavedra J, Henson DE (2000) Tumours of gallbladder and extrahepa-
tic bile ducts Fascicle 23, 3rd edn, Washington, DC: Armed Forces Institute
of Pathology
Albrecht S, von Deimling A, Pietsch T, Giangaspero F, Brandner S, Kleihues
P, Wiestler OD (1994) Microsatellite analysis of loss of heterozygosity on
chromosomes 9q, 11p and 17p in medulloblastomas. Neuropathol Appl
Neurobiol 20: 74–81
Allione F, Eisinger F, Parc P, Noguchi T, Sobol H, Birnbaum D (1998) Loss of
heterozygosity at loci from chromosome arm 22Q in human sporadic
breast carcinomas. Int J Cancer 75: 181–186
Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM (2000) Deﬁni-
tion and reﬁnement of chromosome 8p regions of loss of heterozygosity in
gastric cancer. Clin Cancer Res 6: 1372–1377
Bookstein R, Bova GS, MacGrogan D, Levy A, Isaacs WB (1997) Tumour-
suppressor genes in prostatic oncogenesis: a positional approach. Br J Urol
79(Suppl 1): 28–36
Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B,
Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub
S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna
JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers
and malignant phenotype suppression. J Natl Cancer Inst 93: 691–699
Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC
(2001) Functional identiﬁcation of LZTS1 as a candidate prostate tumour
suppressor gene on human chromosome 8p22. Oncogene 20: 4169–4179
Chaganti SR, Gaidano G, Louie DC, Dalla-Favera R, Chaganti RS (1995)
Diffuse large cell lymphomas exhibit frequent deletions in 9p21-22 and
9q31-34 regions. Genes Chromosomes Cancer 12: 32–36
Chang HJ, Kim SW, Kim YT, Kim WH (1999) Loss of heterozygosity in
dysplasia and carcinoma of the gallbladder. Mod Pathol 12: 763–769
Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR (1999)
Frequent mutations of NF2 and allelic loss from chromosome band
22q12 in malignant mesothelioma: evidence for a two-hit mechanism of
NF2 inactivation. Genes Chromosomes Cancer 24: 238–242
Choi C, Kim MH, Juhng SW, Oh BR (2000) Loss of heterozygosity at chro-
mosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of
the urinary bladder. Int J Cancer 86: 501–505
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic
inactivation of a RAS association domain family protein from the lung
tumour suppressor locus 3p21.3. Nat Genet 25: 315–319
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Gallbladder carcinoma and chromosomes 3p, 8p, 9q and 22q
II Wistuba et al
439
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 432–440Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B,
Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V,
Klein G, Zabarovsky ER (2001) The candidate tumour suppressor gene,
RASSF1A, from human chromosome 3p21.3 is involved in kidney tumour-
igenesis. Proc Natl Acad Sci USA 98: 7504–7509
El-Naggar AK, Coombes MM, Batsakis JG, Hong WK, Goepfert H, Kagan J
(1998) Localization of chromosome 8p regions involved in early tumour-
igenesis of oral and laryngeal squamous carcinoma. Oncogene 16: 2983–
2987
Engleﬁeld P, Foulkes WD, Campbell IG (1994) Loss of heterozygosity on
chromosome 22 in ovarian carcinoma is distal to and is not accompanied
by mutations in NF2 at 22q12. Br J Cancer 70: 905–907
Farrington SM, Cunningham C, Boyle SM, Wyllie AH, Dunlop MG (1996)
Detailed physical and deletion mapping of 8p with isolation of YAC clones
from tumour suppressor loci involved in colorectal cancer. Oncogene 12:
1803–1808
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumourigen-
esis. Cell 61: 759–767
Fisher JC (1958) Multiple mutation theory of carcinogenesis. Nature 181:
651–652
Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, Naka-
mura Y (1995) Isolation of a candidate tumour suppressor gene on
chromosome 8p21.3-p22 that is homologous to an extracellular domain
of the PDGF receptor beta gene. Oncogene 10: 891–895
Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD (2000)
Genome-wide allelotyping of lung cancer identiﬁes new regions of allelic
loss, differences between small cell lung cancer and non-small cell lung
cancer, and loci clustering. Cancer Res 60: 4894–4906
Habuchi T, Devlin J, Elder PA, Knowles MA (1995) Detailed deletion
mapping of chromosome 9q in bladder cancer: evidence for two tumour
suppressor loci. Oncogene 11: 1671–1674
Habuchi T, Luscombe M, Elder PA, Knowles MA (1998) Structure and
methylation-based silencing of a gene (DBCCR1) within a candidate blad-
der cancer tumour suppressor region at 9q32-q33. Genomics 48: 277–288
Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, Akao
T, Sato K, Ogawa O, Knowles MA, Kato T (2001) Hypermethylation at
9q32-33 tumour suppressor region is age-related in normal urothelium
and an early and frequent alteration in bladder cancer. Oncogene 20:
531–537
Huebner K, Garrison PN, Barnes LD, Croce CM (1998) The role of the FHIT/
FRA3B locus in cancer. Annu Rev Genet 32: 7–31
Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M,
Fidanza V, Alder H, Croce CM (1999) The FEZ1 gene at chromosome
8p22 encodes a leucine-zipper protein, and its expression is altered in
multiple human tumours. Proc Natl Acad Sci USA 96: 3928–3933
Ishwad CS, Shuster M, Bockmuhl U, Thakker N, Shah P, Toomes C, Dixon
M, Ferrell RE, Gollin SM (1999) Frequent allelic loss and homozygous
deletion in chromosome band 8p23 in oral cancer. Int J Cancer 80: 25–31
Knudson AG (1985) Hereditary cancer, oncogenes, and antioncogenes.
Cancer Res 45: 1437–1443
Lazcano-Ponce E, Miquel JF, Ferrecio C, Wistuba I, Mun ˜oz N, Alonso de
Ruiz P, Urista G, Herrero R, Nervi F (2001) Epidemiology and Molecular
Pathology of Gallbladder Cancer. Ca Cancer J Clin 51: 349–364
Lerman MI, Minna JD (2000) The 630-kb lung cancer homozygous deletion
region on human chromosome 3p21.3: identiﬁcation and evaluation of the
resident candidate tumour suppressor genes. The International Lung
Cancer Chromosome 3p21.3 Tumour Suppressor Gene Consortium.
Cancer Res 60: 6116–6133
Loeb LA (1991) Mutator phenotype may be required for multistage carcino-
genesis. Cancer Res 51: 3075–3079
Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S,
Gazdar AF, Minna JD (2001) High-resolution chromosome 3p allelotyping
of breast carcinomas and precursor lesions demonstrates frequent loss of
heterozygosity and a discontinuous pattern of allele loss. Am J Pathol
159: 119–130
Miyakawa A, Wang XL, Nakanishi H, Imai FL, Shiiba M, Miya T, Imai Y,
Tanzawa H (1998) Allelic loss on chromosome 22 in oral cancer: possibi-
lity of the existence of a tumour suppressor gene on 22q13. Int J Oncol 13:
705–709
Muscheck M, Sukosd F, Pesti T, Kovacs G (2000) High density deletion
mapping of bladder cancer localizes the putative tumour suppressor gene
between loci D8S504 and D8S264 at chromosome 8p23.3. Lab Invest 80:
1089–1093
Perinchery G, Bukurov N, Nakajima K, Chang J, Hooda M, Oh BR, Dahiya R
(1999) Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in
human prostate cancer. Int J Oncol 14: 495–500
Pineau P, Nagai H, Prigent S, Wei Y, Gyapay G, Weissenbach J, Tiollais P,
Buendia MA, Dejean A (1999) Identiﬁcation of three distinct regions of
allelic deletions on the short arm of chromosome 8 in hepatocellular carci-
noma. Oncogene 18: 3127–3134
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C,
Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir
G, Bijisma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldrige R, Aurias
A, Delattre O, Thomas G (1993) Alteration in a new gene encoding a puta-
tive membrane-organizing protein causes neuro-ﬁbromatosis type 2.
Nature 363: 515–521
Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C, Roberts I,
James L, Cahn A, Bench A, Douglas J, Minna J, Sekido Y, Lerman M, Latif
F, Bergh J, Li H, Lowe N, Ogilvie D, Rabbitts P (1998) Homozygous dele-
tions at 3p12 in breast and lung cancer. Oncogene 17: 1723–1729
Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y (1993) Frequent loss of
heterozygosity on chromosome 22 in hepatocellular carcinoma. Hepatology
17: 794–799
Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schro-
der FH, Faber PW, Bosman FT (1994) Loss of heterozygosity of
chromosome 8 microsatellite loci implicates a candidate tumour suppres-
sor gene between the loci D8S87 and D8S133 in human prostate cancer.
Cancer Res 54: 6061–6064
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S,
Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah
S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S,
Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR,
Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali
JB, Ward S, Green AJ, Yates JR, Kwiatkowski J, Henske EP, Short MP,
Haines JH, Jozwiak S, Kwiatkowski DJ (1997) Identiﬁcation of the tuber-
ous sclerosis gene TSC1 on chromosome 9q34. Science 277: 805–808
Virmani AK, Rahti A, Zo ¨chbauer-Mu ¨ller S, Sacchi N, Fukuyama Y, Bryant D,
Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF (2000)
Promoter methylation and silencing of the retinoic acid receptor beta gene
in lung carcinomas. J Natl Cancer Inst 92: 1303–1307
Wistuba II, Albores-Saavedra J (1999) Genetic abnormalities involved in the
pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 6:
237–244
Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B,
Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF (1998)
Comparison of molecular changes in lung cancers in HIV-positive and
HIV- indeterminate subjects. JAMA 279: 1554–1559
Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon
JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna
JD (2000) High resolution chromosome 3p allelotyping of human lung
cancer and preneoplastic/preinvasive bronchial epithelium reveals multi-
ple, discontinuous sites of 3p allele loss and three regions of frequent
breakpoints. Cancer Res 60: 1949–1960
Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B,
Minna JD, Gazdar AF (1999a) Allelic losses at chromosome 8p21-23 are
early and frequent events in the pathogenesis of lung cancer. Cancer Res
59: 1973–1979
Wistuba II, Tang M, Maitra A, Alvarez H, Troncoso P, Pimentel F, Gazdar AF
(2001) Genome-wide allelotyping analysis reveals multiple sites of allelic
loss in gallbladder carcinoma. Cancer Res 61: 3795–800
Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF
(1999b) Sequential molecular abnormalities are involved in the multistage
development of squamous cell lung carcinoma. Oncogene 18: 643–650
Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani, AK, Roa I, Albores-
Saavedra J, Gazdar AF (1995) Allele speciﬁc mutations involved in the
pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 55:
2511–2515
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Gallbladder carcinoma and chromosomes 3p, 8p, 9q and 22q
II Wistuba et al
440
British Journal of Cancer (2002) 87(4), 432–440 ã 2002 Cancer Research UK